Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
Ipamorelin and CJC-1295 are synthetic peptides studied as growth-hormone secretagogues compounds that act on the body's own machinery for releasing growth hormone (GH) rather than supplying GH directly
Regulatory Status Summary (as of July 29, 2026) Category 2 restricted status: Removed (April 2026) FDA approval: None USP/NF monograph: None 503A Bulks List: PCAC recommended inclusion (July 2324, 2026, nonbinding)
Some pharmacies have limited-time introductory offers, where the first few doses are sold at a relatively low price
Therefore, a combined intervention targeting the complex regulatory network formed by HMGCR, TNF-, and Hedgehog signaling pathways may offer novel therapeutic approaches to overcome tumor resistance and metastasis, thereby opening new avenues and strategies for cancer treatment
It is classified as a triple hormone receptor agonist, which means it activates three separate hormone pathways in the body at the same time
.png?w=1280&max-h=720&fit=crop&auto=format)
